- Home
- NUVB vs BFST Comparison
NUVB vs BFST Comparison
Compare NUVB & BFST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVB
- BFST
- Stock Information
- Founded
- NUVB 2018
- BFST 2006
- Country
- NUVB United States
- BFST United States
- Employees
- NUVB N/A
- BFST N/A
- Industry
- NUVB Biotechnology: Pharmaceutical Preparations
- BFST Major Banks
- Sector
- NUVB Health Care
- BFST Finance
- Exchange
- NUVB Nasdaq
- BFST Nasdaq
- Market Cap
- NUVB 837.0M
- BFST 783.9M
- IPO Year
- NUVB N/A
- BFST 2018
- Fundamental
- Price
- NUVB $2.75
- BFST $23.78
- Analyst Decision
- NUVB Strong Buy
- BFST Strong Buy
- Analyst Count
- NUVB 6
- BFST 3
- Target Price
- NUVB $8.00
- BFST $30.00
- AVG Volume (30 Days)
- NUVB 4.6M
- BFST 95.2K
- Earning Date
- NUVB 08-07-2025
- BFST 07-28-2025
- Dividend Yield
- NUVB N/A
- BFST 2.35%
- EPS Growth
- NUVB N/A
- BFST 3.92
- EPS
- NUVB N/A
- BFST 2.51
- Revenue
- NUVB $14,355,000.00
- BFST $291,096,000.00
- Revenue This Year
- NUVB $98.78
- BFST $25.48
- Revenue Next Year
- NUVB $489.71
- BFST $17.20
- P/E Ratio
- NUVB N/A
- BFST $9.46
- Revenue Growth
- NUVB 900.35
- BFST 17.48
- 52 Week Low
- NUVB $1.54
- BFST $20.07
- 52 Week High
- NUVB $3.46
- BFST $30.30
- Technical
- Relative Strength Index (RSI)
- NUVB 67.35
- BFST 44.72
- Support Level
- NUVB $2.18
- BFST $22.62
- Resistance Level
- NUVB $2.55
- BFST $24.71
- Average True Range (ATR)
- NUVB 0.18
- BFST 0.61
- MACD
- NUVB 0.03
- BFST 0.04
- Stochastic Oscillator
- NUVB 82.48
- BFST 46.40
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.
About BFST Business First Bancshares Inc.
Business First Bancshares Inc is a bank holding company. The company's services include personal and commercial banking, treasury management, and wealth solutions. It provides a range of financial services to small-to-midsized businesses and professionals. The company generates majority of its revenues from interest income on loans, customer service and loan fees, and interest income from securities.